This article is an
autobiography or has been extensively edited by the subject or by someone connected to the subject. (May 2024) |
Justin Stebbing is a British oncology doctor and cancer researcher. He is a professor of biomedical sciences at Anglia Ruskin University [1] and practices with the private sector Phoenix Hospital Group in London. [2] He specialises in a range of solid malignancies, including difficult cases with few conventional options and has published over 700 papers, the majority regarding therapeutic and translational approaches.[ citation needed]
Stebbing is Editor-in-Chief of the journal Oncogene. [3] He is also a visiting professor of cancer medicine and oncology at Imperial College, London [4]
Stebbing graduated from Trinity College, Oxford.[ citation needed] After completion of junior doctor positions in Oxford, he trained on the residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career at The Royal Marsden and then St Bartholomew's Hospitals. His PhD research investigated the interplay between the immune system and cancer including the role of viruses. [5] [6] In 2007, he was appointed a senior lecturer, and then in 2009 a full professor, at Imperial College London. [7] In 2011, the National Institute for Health and Care Research awarded Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and targeted precision medicine approaches. [8]
Stebbing has published over 700 peer-reviewed papers [9] and has an h-index of 89 according to Google Scholar. [10] He is Editor-in-Chief of the journal Oncogene, [11] a Fellow of the Royal College of Physicians, [12] the American Society for Clinical Investigation [13] and the Royal College of Pathologists. [14]
The charity Action Against Cancer was set up to support Stebbing's work. [15] In cancer, some of his most cited papers include the discovery of the role of the oncogene LMTK3 across malignancies, the network of microRNAs induced by the estrogen receptor, and work on HIV and AIDS cancers. [16] [17] [18] [19] He has undertaken extensive work on biosimilars, [20] cheaper versions of expensive biologic drugs designed to democratise access to these. [21]
During the Covid-19 pandemic in early 2020, Stebbing used artificial intelligence to identify baricitinib as a potential drug treatment. [22] [23] He led studies that showed that the drug reduced mortality in COVID-19 hospitalised patients with pneumonia, which led to the drug being authorised by the US Food and Drug Administration in October 2020 as an Emergency Use Authorization at first in combination with remdesivir, then alone. [24] Much of this work is summarized by editorials he wrote in The New England Journal of Medicine and Lancet Respiratory Medicine. [25] [26] Stebbing wrote a book, Witness to COVID, 2020 [27] [28] describing its discovery, trials, studies and approval. [29] [30] In 2024, he was co-senior author on a paper in Nature Communications [31] using invariant natural killer T cells as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome (ARDS), the first time these cells have been used in the clinic. [32]
In 2020, Stebbing was investigated by the General Medical Council over allegations that he failed to provide adequate care to eleven patients he had cared for between 2014 and 2017. [33] [34] The case focused on whether Stebbing had prescribed inappropriate courses of treatment in patients whose cancers were too advanced to benefit from the treatment. [35] Following a Medical Practitioners Tribunal Service misconduct hearing, the GMG suspended Stebbing from the UK medical register for nine months in 2022. [36]
Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications. [37] He has combined his medical career with investing, and he has worked with Atticus Capital, Lansdowne Partners, Vitruvian Partners and Chaired the Board of BB Healthcare Trust. [38] He is senior oncology advisor to Clinical ink [39] and chairs the ZephyrAI scientific advisory board. [40] He is senior VP of clinical strategy and innovation [41] at Graviton Biosciences focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of ROCK2.
This article is an
autobiography or has been extensively edited by the subject or by someone connected to the subject. (May 2024) |
Justin Stebbing is a British oncology doctor and cancer researcher. He is a professor of biomedical sciences at Anglia Ruskin University [1] and practices with the private sector Phoenix Hospital Group in London. [2] He specialises in a range of solid malignancies, including difficult cases with few conventional options and has published over 700 papers, the majority regarding therapeutic and translational approaches.[ citation needed]
Stebbing is Editor-in-Chief of the journal Oncogene. [3] He is also a visiting professor of cancer medicine and oncology at Imperial College, London [4]
Stebbing graduated from Trinity College, Oxford.[ citation needed] After completion of junior doctor positions in Oxford, he trained on the residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career at The Royal Marsden and then St Bartholomew's Hospitals. His PhD research investigated the interplay between the immune system and cancer including the role of viruses. [5] [6] In 2007, he was appointed a senior lecturer, and then in 2009 a full professor, at Imperial College London. [7] In 2011, the National Institute for Health and Care Research awarded Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and targeted precision medicine approaches. [8]
Stebbing has published over 700 peer-reviewed papers [9] and has an h-index of 89 according to Google Scholar. [10] He is Editor-in-Chief of the journal Oncogene, [11] a Fellow of the Royal College of Physicians, [12] the American Society for Clinical Investigation [13] and the Royal College of Pathologists. [14]
The charity Action Against Cancer was set up to support Stebbing's work. [15] In cancer, some of his most cited papers include the discovery of the role of the oncogene LMTK3 across malignancies, the network of microRNAs induced by the estrogen receptor, and work on HIV and AIDS cancers. [16] [17] [18] [19] He has undertaken extensive work on biosimilars, [20] cheaper versions of expensive biologic drugs designed to democratise access to these. [21]
During the Covid-19 pandemic in early 2020, Stebbing used artificial intelligence to identify baricitinib as a potential drug treatment. [22] [23] He led studies that showed that the drug reduced mortality in COVID-19 hospitalised patients with pneumonia, which led to the drug being authorised by the US Food and Drug Administration in October 2020 as an Emergency Use Authorization at first in combination with remdesivir, then alone. [24] Much of this work is summarized by editorials he wrote in The New England Journal of Medicine and Lancet Respiratory Medicine. [25] [26] Stebbing wrote a book, Witness to COVID, 2020 [27] [28] describing its discovery, trials, studies and approval. [29] [30] In 2024, he was co-senior author on a paper in Nature Communications [31] using invariant natural killer T cells as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome (ARDS), the first time these cells have been used in the clinic. [32]
In 2020, Stebbing was investigated by the General Medical Council over allegations that he failed to provide adequate care to eleven patients he had cared for between 2014 and 2017. [33] [34] The case focused on whether Stebbing had prescribed inappropriate courses of treatment in patients whose cancers were too advanced to benefit from the treatment. [35] Following a Medical Practitioners Tribunal Service misconduct hearing, the GMG suspended Stebbing from the UK medical register for nine months in 2022. [36]
Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications. [37] He has combined his medical career with investing, and he has worked with Atticus Capital, Lansdowne Partners, Vitruvian Partners and Chaired the Board of BB Healthcare Trust. [38] He is senior oncology advisor to Clinical ink [39] and chairs the ZephyrAI scientific advisory board. [40] He is senior VP of clinical strategy and innovation [41] at Graviton Biosciences focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of ROCK2.